Clinical Trials
- Prostate Cancer
A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Date05/23/2022
- Phase 1 Cancers, Prostate Cancer
A Phase 1, Open-label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies.
- Ages18 years and older
- GenderMale only
- Date06/01/2022
- Prostate Cancer
Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
- Ages30 years - 80 years
- GenderBoth
- Date06/11/2015
- Other Cancers, Prostate Cancer
Customized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)
- Date09/28/2021
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Lung Cancer, Other Cancers, Pancreatic Cancer, Prostate Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Ages18 years and older
- GenderBoth
- Date06/13/2022
- Prostate Cancer
Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
- Ages45 years - 80 years
- GenderMale only
- Date05/05/2021
- Prostate Cancer
MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
- Ages18 years - 80 years
- GenderMale only
- Date06/24/2013
- Bladder Cancer, Brain and Other Nervous System Cancers, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Lymphoma
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
- Date05/27/2022
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Lymphoma
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Date04/27/2022
- Prostate Cancer
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer
- Ages18 years and older
- GenderMale only
- Date06/01/2022